Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

NurExone Biologic announces important test results

By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...
Research | December 11, 2024 |

StockTalk Podcast Exclusive: Investing Guru Rick Rule

Welcome to StockTalk – the new Stockhouse podcast series that brings you behind-the- scenes insights into trending topics from capital markets influencers and entrepreneurs... broadcasting from the heart of the financial district in downtown Vancouver. In this episode,...
Stockhouse Media | August 7, 2019 |

StockTalk Podcast Exclusive: The Incomparable Bruce Linton

Welcome to StockTalk – the new Stockhouse podcast series that brings you behind-the- scenes insights into trending topics from capital markets influencers and entrepreneurs…broadcasting from the heart of the financial district in downtown Vancouver. In this episode, Sto...
Stockhouse Media | August 2, 2019 |

Stockhouse Media Exclusive: The Diamond Report

Dean Taylor knows diamonds. In fact, the CEO of Diamcor Mining Inc. (DMI) ( TSX-V:DMI , OTC:DMIFF , Forum ) has been running DMI since 2007, and that's a long at the helm in the mining space. His company is an established, production-based diamond miner with propertie...
Stockhouse Media | March 16, 2020 |

StockTalk Exclusive! Cannabis Industry Icon Steve DeAngelo

Steve DeAngelo chats with Cindy Broad for the Arcview 2020 Vision Series First Forum: Cannabis Investing for a New Decade. Listen to Steve's colourful commentary on everything from surviving the dip, to what's next for the industry, to his views on psychedelics......
Cindy Broad | February 11, 2020 |

StockTalk Exclusive Interviews: Mining CEOs and Industry Experts

From March 1 - 4, 2020, Stockhouse Media reported LIVE from the Prospectors & Developers Association of Canada (PDAC) convention floor with interviews, live reports, and news updates from many of the mining industry’s major movers and shakers. Thousand...
Stockhouse Media | March 16, 2020 |

StockTalk Exclusive Interviews: Getting to Know Graphite, Gold, Copper and More

PDAC 2020 Highlights From March 1 - 4, 2020, Stockhouse Media reported LIVE from the Prospectors & Developers Association of Canada (PDAC) convention floor with interviews, live reports, and news updates from many of the mining industry’s major mo...
Stockhouse Media | March 17, 2020 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. Just a few days after reporting third quarter 2019 earnings, late-stage biotechnology company Iovance Biothe...
Streetwise Reports | November 12, 2019 |

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...
Streetwise Reports | December 5, 2019 |
1 2 3 4 5 6 7 8 9 10 ...